<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581009</url>
  </required_header>
  <id_info>
    <org_study_id>HS#2001-1616</org_study_id>
    <nct_id>NCT00581009</nct_id>
  </id_info>
  <brief_title>The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients</brief_title>
  <official_title>The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of sleep deprivation treatment in accelerating&#xD;
      antidepressant responses when administered during the first week of medications and&#xD;
      augmenting a sustained response with chronobiological interventions. Sleep deprivation and&#xD;
      chronobiological augmentation may offer a rapid and sustained antidepressant response in mood&#xD;
      disorder patients treated with medication, sleep deprivation, bright light therapy and sleep&#xD;
      phase advance compared with medication only. The chronobiological treatment is rapid,&#xD;
      non-invasive and has few side effects and could be of significant clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2001</start_date>
  <completion_date type="Actual">December 9, 2011</completion_date>
  <primary_completion_date type="Actual">December 9, 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Score for Depression</measure>
    <time_frame>within the first seven weeks (plus or minus 1 day) after sleep deprivation and chronobiological therapy</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chronobiological augmentation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medication only group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD Mechanism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chronobiological augmentation</intervention_name>
    <description>Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline, lithium</intervention_name>
    <description>Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.&#xD;
Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zoloft</other_name>
    <other_name>Lithium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>one night of sleep deprivation and two FDG PET scans</intervention_name>
    <description>MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.</description>
    <arm_group_label>MDD Mechanism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria include:&#xD;
&#xD;
          1. Subjects must be English speaking&#xD;
&#xD;
          2. Subjects must have either bipolar or unipolar depression diagnosis or be a normal&#xD;
             control.&#xD;
&#xD;
          3. Subjects must be between : 18 to 75&#xD;
&#xD;
        Non-English speaking subjects will be excluded since scales for measuring depression have&#xD;
        not been validated in languages other than English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria include:&#xD;
&#xD;
          1. Suicidality, or psychosis&#xD;
&#xD;
          2. Unstable medical conditions&#xD;
&#xD;
          3. Epilepsy, serious head injury, or other significant neurological disorders&#xD;
&#xD;
          4. Dementia, mental retardation (moderate or severe), coma&#xD;
&#xD;
          5. Prior exposure to radiation which might cause the subject to exceed standard&#xD;
             guidelines&#xD;
&#xD;
          6. Substance abuse or alcoholism in the past six months&#xD;
&#xD;
          7. Unreliability or inability to adhere to the requirements of the study&#xD;
&#xD;
          8. Irregular sleep-wake schedules (nightshift, jet lag)&#xD;
&#xD;
          9. Use of CNS medications which may affect sleep or functional brain imaging (i.e., use&#xD;
             of sleeping pills, antidepressants or other mood stabilizers or other medications&#xD;
             which may affect the sleep EEG)&#xD;
&#xD;
         10. Sleep apnea, periodic limb movements of sleep, narcolepsy, circadian sleep phase&#xD;
             disorders&#xD;
&#xD;
         11. Donation or loss of blood (&gt;400 ml) within the past month&#xD;
&#xD;
         12. Current or very recent intercurrent illnesses, painful conditions or other disorders,&#xD;
             which in the judgement of the investigators, might invalidate the scientific goals of&#xD;
             the study or pose undesirable difficulties or risks for the subject.&#xD;
&#xD;
         13. Hamilton Rating Scale of Depression (HRSD-17 items)&lt;17 unless subject is a normal&#xD;
             control subject.&#xD;
&#xD;
         14. Pregnancy or breast feeding&#xD;
&#xD;
         15. Individuals who would be unable to undergo a magnetic resonance imaging (MRI) scan,&#xD;
             for example, individuals who suffer from claustrophobia, or who have metal clips in&#xD;
             their body.&#xD;
&#xD;
         16. Unable to cease taking psychoactive medications which are not part of this protocol&#xD;
             (2-5 weeks) prior to PET scans.&#xD;
&#xD;
         17. Patients with previous history of significant adverse reactions to sertraline or&#xD;
             sertraline-like drugs or other SSRI's such as Paxil or Prozac&#xD;
&#xD;
         18. Subjects with diagnosis of eating disorder/bulimia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry F Chaitin, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093 - 0603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep deprivation</keyword>
  <keyword>antidepressant</keyword>
  <keyword>depression</keyword>
  <keyword>chronobiological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Deprivation</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

